Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria (original) (raw)
A Comparison of Three Phosphodiesterase Type III Inhibitors on Mechanical and Metabolic Function in Guinea Pig Isolated Hearts
Eike Martin
Anesthesia & Analgesia, 2006
View PDFchevron_right
Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram
M SHAHID
Naunyn-schmiedebergs Archives of Pharmacology, 1990
View PDFchevron_right
ANTIARRHYTHMIC ACTIVITY OF SOME ISOQUINOLINE DERIVATIVES DETERMINED BY A RAPID SCREENING PROCEDURE IN THE MOUSE"2
JAMILETE CAMELA
View PDFchevron_right
Cardioprotective Effect Afforded by Transient Exposure to Phosphodiesterase III Inhibitors
Hisakazu Ogita
Circulation, 2001
View PDFchevron_right
Classification of Phosphodiesterases and the Therapeutic Effects of their Inhibitors (Review
IJSES Editor
View PDFchevron_right
Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts
Lei Xi
Acta Pharmacologica Sinica, 2008
View PDFchevron_right
Cardioprotective Effect Afforded by Transient Exposure to Phosphodiesterase III Inhibitors: The Role of Protein Kinase A and p38 Mitogen-Activated Protein Kinase
Shoji Sanada
Circulation, 2001
View PDFchevron_right
A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases
Yashi Agarwal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017
View PDFchevron_right
The Inotropic Effect of the Active Metabolite of Levosimendan, OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium
Finn Olav Levy, Ornella Manfra, T. Skomedal, K. Andressen
PLOS ONE, 2015
View PDFchevron_right
Cardiovascular and other pharmacological approaches of phosphodiesterase enzyme inhibitors
Md Habban Akhter
2013
View PDFchevron_right
Positive Inotropic Effect of the Inhibition of Cyclic GMP-Stimulated 3', 5'-Cyclic Nucleotide Phosphodiesterase (PDE~ 2) on Guinea Pig Left Atria in Eu-and …
Rudolf Gesztelyi
General physiology and …, 2003
View PDFchevron_right
Current Status of Phosphodiesterase Inhibitors in the Treatment of Congestive Heart Failure
Raimund Erbel
Drugs, 1992
View PDFchevron_right
Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization
ERIC DELPY
British Journal of Pharmacology, 1996
View PDFchevron_right
(Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase
Paul Erhardt
Journal of Medicinal Chemistry, 1993
View PDFchevron_right
The effect duration of selective phosphodiesterase inhibitors in the guinea pig
Francesco Marchini
Life Sciences, 1998
View PDFchevron_right
The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig
Jouko Levijoki
European Journal of Pharmacology, 2004
View PDFchevron_right
Potent Cardioprotective Effect of the 4-Anilinoquinazoline Derivative PD153035: Involvement of Mitochondrial KATP Channel Activation
Fernanda Cerqueira
PLOS One, 2010
View PDFchevron_right
A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts
Alexis Rump
British Journal of Pharmacology, 1994
View PDFchevron_right
The mechanism by which adenosine and cholinergic agents reduce contractility in rat myocardium. Correlation with cyclic adenosine monophosphate and receptor densities
Joel Linden
Circulation Research, 1985
View PDFchevron_right
The Mechanism by Which Adenosine and Cholinergic Agents Reduce Contractility in Rat Myocardium
Amrat Patel
View PDFchevron_right
Phosphodiesterase inhibitors and the cardiovascular system
Robert Feneck
Continuing Education in Anaesthesia, Critical Care & Pain, 2007
View PDFchevron_right
Synthesis, Docking Studies, Pharmacological Activity and Toxicity of a Novel Pyrazole Derivative (LQFM 021)—Possible Effects on Phosphodiesterase
Luciano Lião
Chemical and Pharmaceutical Bulletin, 2013
View PDFchevron_right
Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1
Jennifer Liras
Journal of medicinal chemistry, 2018
View PDFchevron_right
Electrophysiological effects of disopyramide and quinidine on guinea pig atria and canine cardiac purkinje fibers. Dependence on underlying cholinergic tone
Michael Mirro
Circulation Research, 1980
View PDFchevron_right
Novel diazinone derivatives separate myofilament Ca2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium
inge lues
Circulation Research, 1992
View PDFchevron_right
Ischemia-dependent efficacy of phosphodiesterase inhibition☆
Irvin Krukenkamp
The Annals of Thoracic Surgery, 1994
View PDFchevron_right
Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5
Nattakarn Pobsuk
Bioorganic & Medicinal Chemistry Letters, 2018
View PDFchevron_right
Phosphodiesterase inhibition and Ca2+ sensitization
Michael Fluss
Molecular and Cellular Biochemistry, 1996
View PDFchevron_right
Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue
Brendan Price
Biochemical Pharmacology, 1987
View PDFchevron_right
Effect of an antihypertensive hydrazine derivative on Ca2+ current of single frog cardiac cells
giau tran
European Journal of Pharmacology: Molecular Pharmacology, 1993
View PDFchevron_right